NFKB1 and metabolic dysfunction-associated steatohepatitis: The administration of silybin in a nonalcoholic steatohepatitis (NASH) mouse model showed that this compound decreased significantly the elevation of p-IKKα/β which is produced by the NASH in liver [78], allowing the blocking of NF-κB.